Otavio Bellwanger in conversation with Ulf Landmesser
ACT: Acetylcystein for the Prevention of Contract-Induced nephropaThy

Christoph Kaiser in conversation with Thomas Luscher
BASKET PROVE: the BASKET PROspective Evaluation Examination (BASKET PROVE)

Stephen Nicholls in conversation with Ulf Landmesser
Results of the First Major Clinical Trial of an Oral Agent Inducing Apo A1 Synthesis: A New Approach to HDL Raising and CVR Risk Modification

Peter Kowey in conversation with Ulf Landmesser
Efficacy and Safety of Prescription Omega-3-Acid Ethyl Esters (P-OM3) for the Prevention of Recurrent Symptomatic Atrial Fibrillation (AF)

William Hiatt in conversation with Ulf Landmesser
NV1FGF Gene Therapy on Amputation-Free Survival in Critical Lib Ischemia – Phase 3 Randomized Double-Blind Placebo-Controlled Trial

Christopher Cannon in conversation with Ulf Landmesser
DEFINE: Determining the EFficacy and Tolerability of CETP INhibition With AnacEtrapid

Peter Sever in conversation with Thomas Lüscher
ASCOT: The Anglo-Scandinavian Cardiac Outcomes Trial

Murray Esler in conversation with Thomas Lüscher
Symplicity HTM-2: International, Multicenter, Prospective, Randomized, Controlled Trial of Endovascular Selective Renal Sympathetic Denervation for the Treatment of Hypertension

Ron Peters in conversation with Ulf Landmesser
RESPONSE: Effect of a nurse coordinated prevention program on cardiovascular risk after an acute coronary syndrome: Main results of the RESPONSE trial.

Sanjit Jolly in conversation with Thomas Lüscher
FUTURA OASIS 8 : A randomised trial comparing two regimens of adjunctive intravenous unfractionated heparin during PCI in high-risk patients with non-STE-ACS treated with fondaparinux.